Alnylam is heavily dependent on its heart drug Amvuttra for growth — and sales have been slowing. Local authorities and relevant stakeholders are closely monitoring the situation as fresh developments unfold on the ground. Officials noted that further verified updates and administrative measures will be shared following a detailed review.